"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 7 | 2 | 9 |
| 1997 | 16 | 1 | 17 |
| 1998 | 17 | 2 | 19 |
| 1999 | 11 | 2 | 13 |
| 2000 | 14 | 6 | 20 |
| 2001 | 9 | 5 | 14 |
| 2002 | 16 | 4 | 20 |
| 2003 | 18 | 5 | 23 |
| 2004 | 12 | 10 | 22 |
| 2005 | 29 | 8 | 37 |
| 2006 | 16 | 18 | 34 |
| 2007 | 16 | 21 | 37 |
| 2008 | 34 | 10 | 44 |
| 2009 | 25 | 22 | 47 |
| 2010 | 30 | 18 | 48 |
| 2011 | 38 | 18 | 56 |
| 2012 | 35 | 17 | 52 |
| 2013 | 42 | 23 | 65 |
| 2014 | 40 | 16 | 56 |
| 2015 | 49 | 31 | 80 |
| 2016 | 64 | 27 | 91 |
| 2017 | 45 | 18 | 63 |
| 2018 | 52 | 23 | 75 |
| 2019 | 45 | 16 | 61 |
| 2020 | 43 | 7 | 50 |
| 2021 | 54 | 14 | 68 |
| 2022 | 20 | 1 | 21 |
| 2023 | 26 | 3 | 29 |
| 2024 | 9 | 20 | 29 |
| 2025 | 40 | 9 | 49 |
| 2026 | 9 | 1 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers. Cancer Med. 2026 Apr; 15(4):e71682.
-
Combination of Antidepressants and Chemotherapeutic Agents to Overcome P-Glycoprotein-Mediated Resistance in Cancer Patients: A Systematic Review. Med Sci (Basel). 2026 Mar 07; 14(1).
-
Established and Emerging Therapies for High-Risk Neuroblastoma. Paediatr Drugs. 2026 Mar; 28(2):159-175.
-
Lipidomic profiles associated with treatment related hepatotoxicity in children with acute lymphoblastic leukemia. Support Care Cancer. 2026 Feb 17; 34(3):209.
-
AquIRE reveals the mechanisms of clinically induced RNA damage and the conservation and dynamics of glycoRNAs. Nucleic Acids Res. 2026 Feb 05; 54(4).
-
Multimerization approach to improve a cell surface plectin binding cancer stem cell targeted peptoid drug-lead. Bioorg Chem. 2026 05; 172:109578.
-
Drug-induced hyponatremia associated with sodium-glucose cotransporter 2 inhibitors, immune checkpoint inhibitors, and targeted anticancer agents. Pol Arch Intern Med. 2026 Mar 24; 136(3).
-
Maintaining oxaliplatin therapy after hypersensitivity reactions: real-world experience with a desensitisation protocol. Clin Exp Med. 2026 Jan 21; 26(1):118.
-
Evaluating the Antiproliferative Effects of Tri(2-Furyl)- and Triphenylphosphine-Gold(I) Pyridyl- and Pyrimidine-Thiolate Complexes. Biomolecules. 2026 01 15; 16(1).
-
Discovery and Characterization of a First-In-Class HCK/BTK PROTAC DFCI-002-06 for the Treatment of MYD88 Mutated B Cell Malignancies. J Med Chem. 2026 Jan 22; 69(2):1119-1134.